41,100 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 41,100 shares of the company's stock, valued at approximately $2,854,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GQG Partners LLC lifted its position in Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after purchasing an additional 5,556,460 shares during the period. Loomis Sayles & Co. L P boosted its stake in Novo Nordisk A/S by 34.2% during the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after buying an additional 2,947,771 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in Novo Nordisk A/S by 73.2% during the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock worth $537,189,000 after acquiring an additional 2,639,693 shares during the period. Two Sigma Investments LP bought a new stake in Novo Nordisk A/S in the fourth quarter worth about $158,657,000. Finally, Clearbridge Investments LLC raised its position in Novo Nordisk A/S by 59.8% in the fourth quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock worth $368,451,000 after acquiring an additional 1,602,549 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 2.8%

Shares of NYSE:NVO opened at $66.76 on Wednesday. The firm has a fifty day moving average of $70.34 and a two-hundred day moving average of $74.21. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $139.74. The firm has a market capitalization of $298.10 billion, a P/E ratio of 19.75, a price-to-earnings-growth ratio of 1.25 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The company had revenue of $11.87 billion for the quarter. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NVO. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating for the company. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Finally, Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.